Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/jci.insight.142270 http://scihub22266oqcxt.onion/10.1172/jci.insight.142270 33476300!7934933!33476300     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       JCI+Insight 2021 ; 6 (4): ä Nephropedia Template TP {{tp|p=33476300|t=2021. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC |pdf=|usr=}}{{33476300}} gab.com Text Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC JO: JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33476300 #FOAvip Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer >/= 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy. Twit Text FOAVip Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC ????JCI Insight http://www.kidney.de/pget.php?&tw=1&pmid=33476300 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33476300 #FOAvip English Wikipedia <ref>{{Cite pmid|33476300}}</ref> Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC #MMPMID33476300 Yoon HA; Bartash R; Gendlina I; Rivera J; Nakouzi A; Bortz RH 3rd; Wirchnianski AS; Paroder M; Fehn K; Serrano-Rahman L; Babb R; Sarwar UN; Haslwanter D; Laudermilch E; Florez C; Dieterle ME; Jangra RK; Fels JM; Tong K; Mariano MC; Vergnolle O; Georgiev GI; Herrera NG; Malonis RJ; Quiroz JA; Morano NC; Krause GJ; Sweeney JM; Cowman K; Allen S; Annam J; Applebaum A; Barboto D; Khokhar A; Lally BJ; Lee A; Lee M; Malaviya A; Sample R; Yang XA; Li Y; Ruiz R; Thota R; Barnhill J; Goldstein DY; Uehlinger J; Garforth SJ; Almo SC; Lai JR; Gil MR; Fox AS; Chandran K; Wang T; Daily JP; Pirofski LA JCI Insight 2021[Feb]; 6 (4): ä PMID33476300show ga Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as a treatment for coronavirus disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200 mL of CCP with a spike protein IgG titer >/= 1:2430 (median 1:47,385) within 72 hours of admission with propensity score-matched controls cared for at a medical center in the Bronx, between April 13 and May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroid use, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared with matched controls, CCP recipients less than 65 years had 4-fold lower risk of mortality and 4-fold lower risk of deterioration in oxygenation or mortality at day 28. For CCP recipients, pretransfusion spike protein IgG, IgM, and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients less than 65 years, but data from controlled trials are needed to validate this finding and establish the effect of aging on CCP efficacy. |Adult[MESH] |Age Factors[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Neutralizing/*administration & dosage/blood/immunology[MESH] |Antibodies, Viral/*administration & dosage/blood/immunology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19/immunology/mortality/*therapy/virology[MESH] |Female[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Immunization, Passive/methods[MESH] |Male[MESH] |Middle Aged[MESH] |New York City/epidemiology[MESH] |Propensity Score[MESH] |Retrospective Studies[MESH] |SARS-CoV-2/*immunology[MESH] |Spike Glycoprotein, Coronavirus/immunology[MESH]Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC (epmc).pdf DeepDyve Pubget Overpricing